Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Efficacy and Safety Evaluation of Nasacort AQ in Children Ages 2-5 Years With Perennial Allergic Rhinitis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00132925
Recruitment Status : Completed
First Posted : August 22, 2005
Last Update Posted : January 11, 2011
Sponsor:
Information provided by:
Sanofi

Brief Summary:

The purposes of this study are:

  • To demonstrate the efficacy of once daily administration of Nasacort AQ 110 µg compared with placebo in children 2-5 years of age with perennial allergic rhinitis; and
  • To assess the safety of Nasacort AQ 110 µg in children 2-5 years of age.

Condition or disease Intervention/treatment Phase
Rhinitis, Allergic, Perennial Drug: Triamcinolone Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 460 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: An Efficacy and Safety Evaluation of Nasacort AQ 110 µg QD Children Ages 2-5 Years With Perennial Allergic Rhinitis
Study Start Date : November 2003
Study Completion Date : February 2006

Resource links provided by the National Library of Medicine





Primary Outcome Measures :
  1. Double-blind phase: Change from baseline in mean daily instantaneous (immediately prior to dosing) Total Nasal Symptom Score (TNSS) over the 4-week double-blind period
  2. Open-label phase: The efficacy variable is the global evaluation of efficacy as rated by the physician and the subject

Secondary Outcome Measures :
  1. Change from baseline: in mean daily reflective (previous 24 hours) TNSS over 4-wk double-blind period
  2. for mean daily instantaneous and reflective TNSS by week
  3. for mean instantaneous and reflective daily scores for nasal stuffiness, nasal discharge, sneezing, nasal itching, and total eye symptoms by week and over four week double-blind period


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 5 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subjects will be male or female children ages 2-5 years with a history of at least 1 year of perennial allergic rhinitis (PAR) with or without seasonal allergic rhinitis (SAR) characterized by nasal stuffiness, nasal discharge, sneezing, nasal itching, and total eye symptoms, and verified by positive skin test or radioallergosorbent test (RAST) to perennial allergen that is present in the subject's environment (documented historical testing performed during the past year will be accepted).
  • Subjects (assisted by a parent/guardian/care provider) must meet an aggregate symptom score of at least 18 (out of a possible 36) for nasal stuffiness, nasal discharge and sneezing for both the reflective (previous 24 hours) and instantaneous symptom scores recorded in the morning
  • Subjects must not have clinically relevant disease other than allergic rhinitis or have clinically relevant deviations from normal on a physical examination.
  • Subjects must not have been recently exposed to rhinitis medications prior to screening
  • Subjects must have no history of hypersensitivity to glucocorticoids or to any excipients of the formulation
  • Subjects undergoing cosyntropin stimulation test must have a morning (8 AM ± 1 hour) pre-stimulation serum cortisol level ≥ 5 µg/dL and 30 minutes post-stimulation serum cortisol level ≥ 18 µg/dL at screening

Exclusion Criteria:

Subjects presenting with any of the following will not be included in the study:

  • Asthma, requiring chronic use of inhaled or systemic corticosteroids in the previous 6 months; upper respiratory tract infection or sinus infection requiring antibiotic therapy within 2 weeks prior to screening or viral upper respiratory tract infection within 7 days of screening.
  • Nasal polyps, deviated septum, or nasal/facial anatomic abnormalities that interfere with symptom evaluation and/or use of intranasal corticosteroids
  • Treatment with more than 2 courses of systemic corticosteroids (each course not exceeding 14 days) within 1 year of screening
  • Use of intranasal or ocular corticosteroids within 2 weeks of screening
  • Use of oral, inhaled, or intravenous corticosteroids within 1 month of screening
  • Use of intramuscular or intra-articular corticosteroids within 3 months of screening
  • Use of high potency dermatological corticosteroids within 1 month of screening
  • Use of oral leukotriene modifiers within 1 week of screening
  • Use of nasal or oral antihistamines or oral or nasal decongestants within 3 days of screening
  • Current or history of cataract or glaucoma
  • Treatment with any investigational product or use of an investigational device within 1 month of screening
  • Immunotherapy, with the exception of a stable maintenance schedule, for at least 1 month prior to screening
  • History of hypersensitivity to glucocorticoids or to any excipients of the formulation
  • Subject is the investigator or any sub-investigator, research assistant, pharmacist, study coordinator, or other staff or relative thereof directly involved in the conduct of the protocol.

Any waiver of these inclusion and exclusion criteria must be approved by the investigator and the sponsor on a case-by-case basis prior to enrolling the subject. This must be documented by both the sponsor and the investigator.

No subject will be allowed to enroll in this study more than once.


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00132925


Locations
Layout table for location information
United States, New Jersey
Sanofi-Aventis, Inc.
Bridgewater, New Jersey, United States, 08807
Sponsors and Collaborators
Sanofi
Investigators
Layout table for investigator information
Study Director: Phyllis Diener, BS, MT (ASCP) Sanofi

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Layout table for additonal information
ClinicalTrials.gov Identifier: NCT00132925     History of Changes
Other Study ID Numbers: XRG5029C_3502
First Posted: August 22, 2005    Key Record Dates
Last Update Posted: January 11, 2011
Last Verified: January 2011

Keywords provided by Sanofi:
allergic rhinitis

Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Rhinitis, Allergic, Perennial
Nose Diseases
Respiratory Tract Diseases
Respiratory Tract Infections
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Triamcinolone
Triamcinolone Acetonide
Triamcinolone hexacetonide
Triamcinolone diacetate
Anti-Inflammatory Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Immunosuppressive Agents
Immunologic Factors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action